Kamada (NASDAQ:KMDA) Stock Crosses Below 200-Day Moving Average – Here’s Why

Kamada Ltd. (NASDAQ:KMDA) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.97 and traded as low as $7.66. Kamada shares last traded at $7.70, with a volume of 50,084 shares.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on KMDA shares. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Stifel Nicolaus set a $11.00 target price on Kamada in a research note on Wednesday, March 11th. Weiss Ratings upgraded Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, May 15th. Finally, Wall Street Zen lowered Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $12.00.

Kamada Price Performance

The business’s 50-day moving average price is $8.18 and its two-hundred day moving average price is $7.97. The company has a market capitalization of $442.83 million, a price-to-earnings ratio of 22.00, a P/E/G ratio of 0.72 and a beta of 0.84.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Kamada had a net margin of 11.21% and a return on equity of 7.73%. The business had revenue of $45.24 million during the quarter, compared to analyst estimates of $46.72 million. As a group, research analysts predict that Kamada Ltd. will post 0.44 EPS for the current year.

Kamada Announces Dividend

The firm also recently declared an annual dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were given a $0.25 dividend. This represents a dividend yield of 305.0%. The ex-dividend date was Monday, March 23rd. Kamada’s payout ratio is presently 54.29%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KMDA. Jane Street Group LLC acquired a new position in Kamada during the first quarter valued at approximately $582,000. Goldman Sachs Group Inc. acquired a new position in Kamada during the first quarter valued at approximately $497,000. Essex Investment Management Co. LLC raised its position in Kamada by 22.4% during the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after purchasing an additional 72,602 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Kamada during the second quarter valued at approximately $472,000. Finally, Bank of America Corp DE raised its position in Kamada by 201.0% during the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock valued at $427,000 after purchasing an additional 41,111 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.